Interestingly, to the best of our knowledge, there are no published studies regarding the potential prognostic impact of the immunohistochemical expression patterns of the CD169+ macrophages in the TME of cHL. The gene discussed is SIGLEC1; the disease is classic Hodgkin lymphoma.